- Home
- BREA vs IMRN Comparison
BREA vs IMRN Comparison
Compare BREA & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- IMRN
- Stock Information
- Founded
- BREA 2022
- IMRN 1994
- Country
- BREA Ireland
- IMRN Australia
- Employees
- BREA N/A
- IMRN N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- IMRN Health Care
- Exchange
- BREA Nasdaq
- IMRN Nasdaq
- Market Cap
- BREA 9.4M
- IMRN 9.2M
- IPO Year
- BREA 2023
- IMRN N/A
- Fundamental
- Price
- BREA $0.72
- IMRN $1.70
- Analyst Decision
- BREA
- IMRN Strong Buy
- Analyst Count
- BREA 0
- IMRN 1
- Target Price
- BREA N/A
- IMRN $5.00
- AVG Volume (30 Days)
- BREA 88.4K
- IMRN 53.5K
- Earning Date
- BREA 01-03-2025
- IMRN 06-17-2025
- Dividend Yield
- BREA N/A
- IMRN N/A
- EPS Growth
- BREA N/A
- IMRN N/A
- EPS
- BREA N/A
- IMRN N/A
- Revenue
- BREA $2,988,009.00
- IMRN $4,048,286.00
- Revenue This Year
- BREA N/A
- IMRN N/A
- Revenue Next Year
- BREA N/A
- IMRN N/A
- P/E Ratio
- BREA N/A
- IMRN N/A
- Revenue Growth
- BREA 151.51
- IMRN 82.90
- 52 Week Low
- BREA $0.50
- IMRN $1.50
- 52 Week High
- BREA $1.95
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- BREA 57.96
- IMRN 43.37
- Support Level
- BREA $0.66
- IMRN $1.69
- Resistance Level
- BREA $0.72
- IMRN $1.89
- Average True Range (ATR)
- BREA 0.04
- IMRN 0.17
- MACD
- BREA 0.00
- IMRN -0.01
- Stochastic Oscillator
- BREA 67.84
- IMRN 34.06
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.